Applied Therapeutics(APLT) - 2025 Q1 - Quarterly Results

Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results "We remain focused on preparing for potential regulatory interactions regarding govorestat in both Classic Galactosemia and Sorbitol Dehydrogenase ("SORD") Deficiency," said Les Funtleyder, Interim CEO and CFO of Applied Therapeutics. "As we continue to optimize our strategy for our late-stage programs, we have also made key senior appointments across regulatory, medical and quality affairs functions to bolster our capabilities. ...